<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Neurosci.</journal-id>
<journal-title>Frontiers in Neuroscience</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Neurosci.</abbrev-journal-title>
<issn pub-type="epub">1662-453X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fnins.2017.00039</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>Perspective</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>CSP&#x003B1;, a Molecular Co-chaperone Essential for Short and Long-Term Synaptic Maintenance</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Lopez-Ortega</surname> <given-names>Elena</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn003"><sup>&#x02020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/404154/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Ruiz</surname> <given-names>Roc&#x000ED;o</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Tabares</surname> <given-names>Lucia</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/6846/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Medical Physiology and Biophysics, School of Medicine, University of Seville</institution> <country>Seville, Spain</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Biochemistry and Molecular Biology, School of Pharmacy, University of Seville</institution> <country>Seville, Spain</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Cintia Roodveldt, Andalusian Molecular Biology and Regenerative Medicine Centre (CABIMER) - CSIC, Spain</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Janice Eva Arlee Braun, University of Calgary, Canada; Konrad Ernst Zinsmaier, University of Arizona, USA</p></fn>
<fn fn-type="corresp" id="fn001"><p>&#x0002A;Correspondence: Lucia Tabares <email>ltabares&#x00040;us.es</email></p></fn>
<fn fn-type="other" id="fn002"><p>This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience</p></fn>
<fn fn-type="present-address" id="fn003"><p>&#x02020;Present Address: Elena Lopez-Ortega, Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>10</day>
<month>02</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>11</volume>
<elocation-id>39</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>12</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>01</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2017 Lopez-Ortega, Ruiz and Tabares.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Lopez-Ortega, Ruiz and Tabares</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>Cysteine string protein &#x003B1; (CSP&#x003B1;) is a vesicle protein located in the presynaptic terminal of most synapses. CSP&#x003B1; is an essential molecular co-chaperone that facilitates the correct folding of proteins and the assembly of the exocytic machinery. The absence of this protein leads to altered neurotransmitter release and neurodegeneration in multiple model systems, from flies to mice. In humans, CSP&#x003B1; mutations are associated with the development of neuronal ceroid lipofuscinosis (NCL), a neurodegenerative disease characterized by intracellular accumulation of lysosomal material. Here, we review the physiological role of CSP&#x003B1; and the pathology resulting from the homozygous deletion of the gene or its mutations. In addition, we investigate whether long-term moderate reduction of the protein produces motor dysfunction. We found that 1-year-old CSP&#x003B1; heterozygous mice display a reduced ability to sustain motor unit recruitment during repetitive stimulation, which indicates that physiological levels of CSP&#x003B1; are required for normal neuromuscular responses in mice and, likely, in humans.</p>
</abstract>
<kwd-group>
<kwd>cysteine string protein</kwd>
<kwd>co-chaperone</kwd>
<kwd>motor neurons</kwd>
<kwd>synaptic transmission</kwd>
<kwd>neuromuscular junction</kwd>
<kwd>CSP&#x003B1;</kwd>
</kwd-group>
<contract-sponsor id="cn001">Ministerio de Ciencia e Innovaci&#x000F3;n<named-content content-type="fundref-id">10.13039/501100004837</named-content></contract-sponsor>
<contract-sponsor id="cn002">Universidad de Sevilla<named-content content-type="fundref-id">10.13039/100009042</named-content></contract-sponsor>
<counts>
<fig-count count="2"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="27"/>
<page-count count="6"/>
<word-count count="3453"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Protein description</title>
<p>Cysteine string protein &#x003B1; (CSP&#x003B1;) (<italic>Dnajc5</italic>) is a highly conserved protein (Figure <xref ref-type="fig" rid="F1">1A</xref>) typically associated with the membrane of synaptic vesicles and secretory granules (Zinsmaier et al., <xref ref-type="bibr" rid="B27">1990</xref>). It contains a DNA-J domain characteristic of Hsp40 co-chaperones. This domain interacts with the 70 kDa heat shock cognate protein (Hsc70) (Braun et al., <xref ref-type="bibr" rid="B2">1996</xref>) and regulates the refolding of client proteins (Hennessy et al., <xref ref-type="bibr" rid="B11">2005</xref>). A linker region connects the DNA-J domain with the cysteine string domain. The cysteine string domain is approximately 25-amino-acids long and contains 13&#x02013;15 cysteines, most of them palmitoylated. Palmitoylation is essential to target CSP&#x003B1; to synaptic vesicles and to promote neurotransmitter release (Arnold et al., <xref ref-type="bibr" rid="B1">2004</xref>). CSP&#x003B1; also contains a C-terminal domain, the function of which is not well-understood.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p><bold>The lack/decrease of CSP&#x003B1; induces structural and functional changes that compromise synaptic maintenance. (A)</bold> Functional domains of the CSP&#x003B1; protein. <bold>(B)</bold> Synaptic release defects (left) and fraction of motor nerve terminals with multilamellar bodies and vacuoles in electron microscopy profiles (right) vs. postnatal age in CSP&#x003B1; KO mice. Graphs summarize numerical values in Ruiz et al. (<xref ref-type="bibr" rid="B16">2008</xref>, <xref ref-type="bibr" rid="B15">2014</xref>) (left) and in Fern&#x000E1;ndez-Chacon et al. (<xref ref-type="bibr" rid="B7">2004</xref>) (right). <bold>(C)</bold> Two parallel chaperone pathways promote efficient SNARE complex formation and normal neurotransmission by regulating SNAP25, through CSP&#x003B1; (pathway I), and synaptobrevin (VAMP2), through &#x003B1;-synuclein (pathway II). The deficit in CSP&#x003B1; produces synaptic dysfunction (Ruiz et al., <xref ref-type="bibr" rid="B16">2008</xref>, <xref ref-type="bibr" rid="B15">2014</xref>; Rozas et al., <xref ref-type="bibr" rid="B14">2012</xref>), whose severity, age of onset, and time course depend on the amount of functional CSP&#x003B1; available. &#x003B1;-synuclein overexpression, however, can avoid the synaptic pathology produced by a defect in pathway I by increasing the formation of SNARE complexes (Sharma et al., <xref ref-type="bibr" rid="B20">2011</xref>, <xref ref-type="bibr" rid="B19">2012a</xref>). <bold>(D)</bold> Hypothetical model of how genetic ablation, gene mutations, or increased CSP&#x003B1; degradation induce a positive loop of neurotransmitter (NT) release deficit, accumulation of misfolded synaptic proteins, and neurodegeneration. In humans, it remains unknown to what extent CSP&#x003B1; haploinsufficiency, sequestration of CSP&#x003B1; in aggregates, and aberrant palmitoylation of CSP&#x003B1; and other proteins contribute to ANCL.</p></caption>
<graphic xlink:href="fnins-11-00039-g0001.tif"/>
</fig>
</sec>
<sec id="s2">
<title>CSP&#x003B1; deficiency and synaptic dysfunction</title>
<p>CSP&#x003B1; is not essential for synaptogenesis, but it is required for normal neurotransmission and neuronal maintenance in flies (Zinsmaier et al., <xref ref-type="bibr" rid="B26">1994</xref>), worms (Kashyap et al., <xref ref-type="bibr" rid="B12">2014</xref>), mice (Fern&#x000E1;ndez-Chacon et al., <xref ref-type="bibr" rid="B7">2004</xref>), and humans (Noskov&#x000E1; et al., <xref ref-type="bibr" rid="B13">2011</xref>). Deletion of the CSP&#x003B1; gene in <italic>Drosophila</italic> produces an embryonic semilethal phenotype, and flies that survive to adulthood present neurotransmitter release alterations and temperature-sensitive paralysis. Synaptic defects in CSP&#x003B1;-null (CSP&#x003B1; KO) mice start early after birth, and death occurs before 3 months of age. Both motor and sensory neurons are affected by the lack of CSP&#x003B1; (Fern&#x000E1;ndez-Chacon et al., <xref ref-type="bibr" rid="B7">2004</xref>; Schmitz et al., <xref ref-type="bibr" rid="B18">2006</xref>). In motor nerve terminals, the first sign of functional alteration appears at 2 weeks of age and consists of repeated bursts of high-frequency spontaneous release (Ruiz et al., <xref ref-type="bibr" rid="B16">2008</xref>) (Figure <xref ref-type="fig" rid="F1">1B</xref>). Only 4 days later, the terminal displays multiple functional alterations such as reduced quantum content, low release probability, increased short-term facilitation during repetitive stimulation, and reduced calcium sensitivity of the secretory machinery (Ruiz et al., <xref ref-type="bibr" rid="B16">2008</xref>, <xref ref-type="bibr" rid="B15">2014</xref>). In addition, the size of the readily releasable pool of synaptic vesicles is decreased (Rozas et al., <xref ref-type="bibr" rid="B14">2012</xref>; Ruiz et al., <xref ref-type="bibr" rid="B15">2014</xref>).</p>
</sec>
<sec id="s3">
<title>CSP&#x003B1; as a molecular co-chaperone</title>
<p>CSP&#x003B1; interacts with several proteins that participate in exo-/endocytosis, including syntaxin, synaptotagmin, N- and P/Q-type calcium channels, and dynamin 1 (for a review see Burgoyne and Morgan, <xref ref-type="bibr" rid="B3">2015</xref>). The functional significance of many of these interactions is not well established. However, one of the best-known functions of CSP&#x003B1; is its role as a co-chaperone (Chamberlain and Burgoyne, <xref ref-type="bibr" rid="B4">2000</xref>; Zinsmaier, <xref ref-type="bibr" rid="B25">2010</xref>; Donnelier and Braun, <xref ref-type="bibr" rid="B6">2014</xref>). CSP&#x003B1; interacts with Hsc70 and together refold client proteins such as SNAP25 (Sharma et al., <xref ref-type="bibr" rid="B20">2011</xref>, <xref ref-type="bibr" rid="B19">2012a</xref>; Zhang et al., <xref ref-type="bibr" rid="B24">2012</xref>). SNAP25 is required for the assembly of the SNARE (soluble N-ethylmaleimide-sensitive factor attachment receptor) complex, formed by synaptobrevin, syntaxin, and SNAP25, which in turn is essential for exocytosis and neurotransmitter release (Figure <xref ref-type="fig" rid="F1">1C</xref>). In CSP&#x003B1; KO mice, both SNAP25 and SNARE complex levels are reduced by half (Chandra et al., <xref ref-type="bibr" rid="B5">2005</xref>).</p>
</sec>
<sec id="s4">
<title>CSP&#x003B1; and neurodegeneration</title>
<p>In CSP&#x003B1; KO motor nerve terminals, hallmarks of degeneration (i.e., vacuoles and multilamellar bodies) appear very early (Fern&#x000E1;ndez-Chacon et al., <xref ref-type="bibr" rid="B7">2004</xref>), even before the evoked release defects become apparent (Figure <xref ref-type="fig" rid="F1">1B</xref>, left graphs). The degeneration is more prominent in cells with high electrical activity, such as motor neurons, photoreceptors, and GABAergic neurons (Fern&#x000E1;ndez-Chacon et al., <xref ref-type="bibr" rid="B7">2004</xref>; Schmitz et al., <xref ref-type="bibr" rid="B18">2006</xref>; Garc&#x000ED;a-Junco-Clemente et al., <xref ref-type="bibr" rid="B8">2010</xref>), suggesting that high synaptic activity potentiates degeneration, which in turn may increase the release deficit (Figure <xref ref-type="fig" rid="F1">1D</xref>).</p>
<p>At the molecular level, it has been proposed that SNAP25 reduction plays a major role in neurodegeneration. This hypothesis is reinforced by the fact that SNAP25 overexpression in CSP&#x003B1; KO mice prevents neurodegeneration (Sharma et al., <xref ref-type="bibr" rid="B19">2012a</xref>). Nevertheless, SNAP25 heterozygous mice, with 50% of the protein, are phenotypically normal and do not develop neurodegeneration (Washbourne et al., <xref ref-type="bibr" rid="B22">2002</xref>), indicating that solely reducing functional SNAP25 is not sufficient to produce the pathology. On the other hand, misfolded SNAP25 could have a dominant negative effect over the normally folded protein copies, or ubiquitinated SNAP25 molecules could accumulate in the proteasome, interfering with its normal function. Surprisingly, however, the fact that pharmacological inhibition of the proteasome increases SNAP25 and SNARE complex levels, and, hence, improves synaptic function in CSP&#x003B1;-depleted cells (Sharma et al., <xref ref-type="bibr" rid="B21">2012b</xref>), has challenged this last hypothesis.</p>
<p>Remarkably, neurodegeneration in CSP&#x003B1; KO mice is prevented when SNARE complexes are increased by the overexpression of &#x003B1;-synuclein (Sharma et al., <xref ref-type="bibr" rid="B20">2011</xref>, <xref ref-type="bibr" rid="B19">2012a</xref>), in spite of the fact that SNAP25 levels are not restored and, presumably, the amount of misfolded SNAP25 is not reduced. Overexpression of the mutated form of &#x003B1;-synuclein A53T in CSP&#x003B1; KO mice restores life span and motor function as well as wild-type (WT) &#x003B1;-synuclein (Chandra et al., <xref ref-type="bibr" rid="B5">2005</xref>). On the other hand, overexpression of A30P &#x003B1;-synuclein does not rescue survival, but can transitorily ameliorate the release deficit and the calcium sensitivity defect in motor nerve terminals of CSP&#x003B1; KO mice (Ruiz et al., <xref ref-type="bibr" rid="B15">2014</xref>). The partial effect of A30P &#x003B1;-synuclein is likely due to its limited ability to increase the formation of SNARE complexes. These findings suggest that two parallel pathways regulate SNARE complex formation (Figure <xref ref-type="fig" rid="F1">1C</xref>), and raise the question of how the neurodegeneration program is activated in the absence of CSP&#x003B1;. The molecular basis of the neurodegeneration is unknown, but a possibility is that neurodegeneration is linked to the reduced ability of the synapse to form SNARE complexes and, therefore, to the mismatch between functional demands and efficient release.</p>
</sec>
<sec id="s5">
<title>CSP&#x003B1; deficiency in humans</title>
<p>Neuronal Ceroid Lipofuscinosis (NCLs) constitute a heterogeneous group of inherited neurodegenerative disorders characterized by lysosomal accumulation of autofluorescent ceroid-lipofuscin aggregates in neurons and other cell types. The clinical symptoms of NCLs include seizures, movement disorders, cognitive deterioration, and progressive dementia, followed by a premature death. The majority of NCL cases affect children, and only 10% of total cases are in adults.</p>
<p>In recent years, two mutations in the gene that encodes CSP&#x003B1;, <italic>DNAJC5</italic>, have been linked to the development of adult-onset NCL (ANCL) (MIM &#x00023;162350). These mutations consist of a point mutation (p.L115R) and an in-frame codon deletion (p.L116&#x00394;), both affecting dileucine residues located in the cysteine string domain of CSP&#x003B1; (Noskov&#x000E1; et al., <xref ref-type="bibr" rid="B13">2011</xref>). This domain is highly palmitoylated and mediates the membrane binding and intracellular targeting of CSP&#x003B1;. Therefore, mutations in this region may explain the diffuse intracellular localization of CSP&#x003B1; observed in the neurons of ANCL patients. Moreover, the mutated forms of CSP&#x003B1; present an increased tendency to self-associate, forming detergent-resistant aggregates. These aggregates interfere with WT CSP&#x003B1; proteins, reducing the co-chaperone function of CSP&#x003B1; in neurons (Noskov&#x000E1; et al., <xref ref-type="bibr" rid="B13">2011</xref>; Greaves et al., <xref ref-type="bibr" rid="B9">2012</xref>; Zhang and Chandra, <xref ref-type="bibr" rid="B23">2014</xref>) (Figure <xref ref-type="fig" rid="F1">1D</xref>), which is likely one of the main reasons why the NCL-linked <italic>DNAJC5</italic> gene mutations display an autosomal dominant (AD) inheritance pattern. Additionally, a dominant effect of mutated CSP&#x003B1; on the palmitoylation pattern of lysosomal and synaptic proteins has been suggested as a mechanism for the development of <italic>DNAJC5</italic>-linked ANCL (Henderson et al., <xref ref-type="bibr" rid="B10">2016</xref>).</p>
</sec>
<sec id="s6">
<title>Long-term moderate CSP&#x003B1; deficiency alters motor responses</title>
<p>Interestingly, only homozygous CSP&#x003B1; KO mice present synaptic defects, while heterozygous mutant mice appear phenotypically normal up to 3 months of age (Fern&#x000E1;ndez-Chacon et al., <xref ref-type="bibr" rid="B7">2004</xref>). Given the late onset of AD-ANCL (around 30 years of age), we studied the motor function of 1-year-old CSP&#x003B1; heterozygous mice. Motor performance was first assessed with Balance and Grip Strength tests (Figure <xref ref-type="fig" rid="F2">2A</xref>). The balance was measured by placing the mouse on a horizontal pole suspended in the air. The pole was rotated manually at a constant speed of one rotation cycle per second (Figure <xref ref-type="fig" rid="F2">2A</xref> left). The grip strength test consisted of suspending the mouse from the pole by its forelimbs (Figure <xref ref-type="fig" rid="F2">2A</xref> right). In both trials, the amount of time the mouse remained suspended from the pole (maximum 10 s) was measured. Two sessions separated by 1 week were performed for each test (Figure <xref ref-type="fig" rid="F2">2B</xref>). Data obtained from the neurological tests showed no significant differences between WT and CSP&#x003B1; heterozygous mice, in either balance or grip strength.</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption><p><bold>The neuromuscular function of 1-year-old CSP&#x003B1; heterozygous mice is altered. (A,B)</bold> Balance and grip strength tests show no significant differences between CSP&#x003B1; heterozygous (<italic>n</italic> &#x0003D; 27) and WT mice (<italic>n</italic> &#x0003D; 9). The plot illustrates the average values obtained in three replicates/session for each genotype (Mann-Whitney U test). <bold>(C)</bold> Representative recordings of CMAPs in a CSP&#x003B1;<sup>&#x0002B;/&#x0002B;</sup> mouse after supramaximal stimulation of the sciatic nerve (1st and 15th responses at different stimulation frequencies). <bold>(D)</bold> Depression of the neuromuscular responses (CMAP normalized amplitude) is significantly larger in CSP&#x003B1;<sup>&#x0002B;/&#x02212;</sup> (<italic>n</italic> &#x0003D; 25) than in WT mice (<italic>n</italic> &#x0003D; 7) during stimulation trains at 20, 50, and 100 Hz. <bold>(E)</bold> Maximal depression of the neuromuscular response (normalized) at different stimulation frequencies in CSP&#x003B1;<sup>&#x0002B;/&#x02212;</sup> (<italic>n</italic> &#x0003D; 24&#x02013;25) and WT mice (<italic>n</italic> &#x0003D; 7) (Mann-Whitney U test). Either sex experimental mice (C57BL/6 background) were used. The mouse line was kindly donated by Dr. S&#x000FC;dhof. All experiments were performed according to the guidelines of the European Council Directive for the Care of Laboratory Animals. The protocol was approved by the Ethics Committee for Animal Experimentation of the Junta de Andaluc&#x000ED;a (ref. 23-11-2015-364).</p></caption>
<graphic xlink:href="fnins-11-00039-g0002.tif"/>
</fig>
<p>Next, the neuromuscular response of CSP&#x003B1; heterozygous mice was studied using electromyography (EMG). Evoked Compound Motor Action Potentials (CMAPs) were recorded from the right lateral gastrocnemius of anesthetized mice. Stimulation needle electrodes were placed at the sciatic notch and the head of the fibula (Ruiz et al., <xref ref-type="bibr" rid="B17">2005</xref>). The active recording electrode was placed in the medial region of the recorded muscle. The reference electrode was inserted at the base of the fifth foot phalanx. The ground electrode was located at the base of the tail. Brief supramaximal stimulation pulses were applied at 10 Hz (2 s), 20 Hz (1 s), 50 Hz (1 s), and 100 Hz (0.5 s). Representative recordings of CMAPs registered during the trains are shown in Figure <xref ref-type="fig" rid="F2">2C</xref>. The study revealed enhanced depression with stimulations between 20 and 100 Hz in CSP&#x003B1; heterozygous mice compared to WT littermates (Figure <xref ref-type="fig" rid="F2">2D</xref>). The mean maximal depression was 5% (20 Hz), 12% (50 Hz), and 25% (100 Hz) lower in CSP&#x003B1; heterozygous than in WT mice, while no significant difference was observed at 10 Hz (Figure <xref ref-type="fig" rid="F2">2E</xref>). Remarkably, the depression in the EMG recordings was similar to that seen in 3-week-old CSP&#x003B1; KO mice (Fern&#x000E1;ndez-Chacon et al., <xref ref-type="bibr" rid="B7">2004</xref>), a phenotype not observed in CSP&#x003B1;<sup>&#x0002B;/&#x02212;</sup> mice up to 3 month of age. These results indicate that, over time, a moderate reduction of CSP&#x003B1; expression alters the ability of the neuromuscular system to respond normally to stimulation.</p>
</sec>
<sec id="s7">
<title>Future directions</title>
<p>The multiple functions of CSP&#x003B1; range from acting as a chaperone, participating in the assembly and dissociation of multi-protein complexes, and regulating Ca<sup>2&#x0002B;</sup> sensitivity for neurotransmitter release. The severe functional and structural changes that take place in the absence of CSP&#x003B1; in invertebrate and vertebrate organism models confirm the importance of this protein in synapse maintenance and neurotransmitter release. In humans, CSP&#x003B1; mutations are associated with the development of AD-ANCL, synaptic degeneration, and neuronal loss. Therefore, although both the reduction of CSP&#x003B1; expression and the presence of CSP&#x003B1; mutations are pathogenic to the synapse, the severity and time course of the neurological impairments may vary from severe, including premature death, to mild, depending on the amount of functional CSP&#x003B1; in each case. The moderate decrease in CSP&#x003B1; and SNARE complexes in neurons over time could result in motor function impairment and, in addition, influence the evolution of common age-related neurodegenerative disorders, such as Alzheimer&#x00027;s and Parkinson&#x00027;s diseases. Future challenges are to identify patients with reduced levels of molecular chaperones (such as CSP&#x003B1;), decipher the mechanisms responsible for the molecular deficit, understand how the homeostasis of the synapse is altered, and determine to what extent the reduction of the chaperones influences the severity of associated neurodegenerative diseases.</p>
</sec>
<sec id="s8">
<title>Author contributions</title>
<p>Experiments shown in Figure <xref ref-type="fig" rid="F2">2</xref> were performed by EL. EL, RR, and LT conceived and wrote the manuscript.</p>
</sec>
<sec id="s9">
<title>Funding</title>
<p>This work was supported by grants from the Spanish Ministry of Science and Innovation (BFU2013&#x02013;43763-P) and the Tatiana Perez de Guzman Foundation to LT. RR was supported by a contract from the <italic>V Plan Propio</italic> of the University of Seville.</p>
<sec>
<title>Conflict of interest statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<ack><p>We are grateful to Rafael Fern&#x000E1;ndez-Chac&#x000F3;n for discussions and comments on the manuscript.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnold</surname> <given-names>C.</given-names></name> <name><surname>Reisch</surname> <given-names>N.</given-names></name> <name><surname>Leibold</surname> <given-names>C.</given-names></name> <name><surname>Becker</surname> <given-names>S.</given-names></name> <name><surname>Prufert</surname> <given-names>K.</given-names></name> <name><surname>Sautter</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2004</year>). <article-title>Structure-function analysis of the cysteine string protein in Drosophila: cysteine string, linker and C terminus</article-title>. <source>J. Exp. Biol.</source> <volume>207</volume>, <fpage>1323</fpage>&#x02013;<lpage>1334</lpage>. <pub-id pub-id-type="doi">10.1242/jeb.00898</pub-id><pub-id pub-id-type="pmid">15010483</pub-id></citation></ref>
<ref id="B2">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braun</surname> <given-names>J. E.</given-names></name> <name><surname>Wilbanks</surname> <given-names>S. M.</given-names></name> <name><surname>Scheller</surname> <given-names>R. H.</given-names></name></person-group> (<year>1996</year>). <article-title>The cysteine string secretory vesicle protein activates Hsc70 ATPase</article-title>. <source>J. Biol. Chem.</source> <volume>271</volume>, <fpage>25989</fpage>&#x02013;<lpage>25993</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.271.42.25989</pub-id><pub-id pub-id-type="pmid">8824236</pub-id></citation></ref>
<ref id="B3">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burgoyne</surname> <given-names>R. D.</given-names></name> <name><surname>Morgan</surname> <given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Cysteine string protein (CSP) and its role in preventing neurodegeneration</article-title>. <source>Semin. Cell Dev. Biol.</source> <volume>40</volume>, <fpage>153</fpage>&#x02013;<lpage>159</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcdb.2015.03.008</pub-id><pub-id pub-id-type="pmid">25800794</pub-id></citation></ref>
<ref id="B4">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chamberlain</surname> <given-names>L. H.</given-names></name> <name><surname>Burgoyne</surname> <given-names>R. D.</given-names></name></person-group> (<year>2000</year>). <article-title>Cysteine-string protein: the chaperone at the synapse</article-title>. <source>J. Neurochem.</source> <volume>74</volume>, <fpage>1781</fpage>&#x02013;<lpage>1789</lpage>. <pub-id pub-id-type="doi">10.1046/j.1471-4159.2000.0741781.x</pub-id><pub-id pub-id-type="pmid">10800920</pub-id></citation></ref>
<ref id="B5">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chandra</surname> <given-names>S.</given-names></name> <name><surname>Gallardo</surname> <given-names>G.</given-names></name> <name><surname>Fernandez-Chacon</surname> <given-names>R.</given-names></name> <name><surname>Schluter</surname> <given-names>O. M.</given-names></name> <name><surname>Sudhof</surname> <given-names>T. C.</given-names></name></person-group> (<year>2005</year>). <article-title>&#x003B1;-synuclein cooperates with CSP&#x003B1; in preventing neurodegeneration</article-title>. <source>Cell</source> <volume>123</volume>, <fpage>383</fpage>&#x02013;<lpage>396</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2005.09.028</pub-id><pub-id pub-id-type="pmid">16269331</pub-id></citation></ref>
<ref id="B6">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Donnelier</surname> <given-names>J.</given-names></name> <name><surname>Braun</surname> <given-names>J. E.</given-names></name></person-group> (<year>2014</year>). <article-title>CSP&#x003B1;-chaperoning presynaptic proteins</article-title>. <source>Front. Cell. Neurosci.</source> <volume>8</volume>:<fpage>116</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2014.00116</pub-id><pub-id pub-id-type="pmid">24808827</pub-id></citation></ref>
<ref id="B7">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fern&#x000E1;ndez-Chacon</surname> <given-names>R.</given-names></name> <name><surname>Wolfel</surname> <given-names>M.</given-names></name> <name><surname>Nishimune</surname> <given-names>H.</given-names></name> <name><surname>Tabares</surname> <given-names>L.</given-names></name> <name><surname>Schmitz</surname> <given-names>F.</given-names></name> <name><surname>Castellano-Munoz</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2004</year>). <article-title>The synaptic vesicle protein CSP&#x003B1; prevents presynaptic degeneration</article-title>. <source>Neuron</source> <volume>42</volume>, <fpage>237</fpage>&#x02013;<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1016/S0896-6273(04)00190-4</pub-id><pub-id pub-id-type="pmid">15091340</pub-id></citation></ref>
<ref id="B8">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ED;a-Junco-Clemente</surname> <given-names>P.</given-names></name> <name><surname>Cantero</surname> <given-names>G.</given-names></name> <name><surname>Gomez-Sanchez</surname> <given-names>L.</given-names></name> <name><surname>Linares-Clemente</surname> <given-names>P.</given-names></name> <name><surname>Martinez-Lopez</surname> <given-names>J. A.</given-names></name> <name><surname>Lujan</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>Cysteine string protein-&#x003B1; prevents activity-dependent degeneration in GABAergic synapses</article-title>. <source>J. Neurosci.</source> <volume>30</volume>, <fpage>7377</fpage>&#x02013;<lpage>7391</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0924-10.2010</pub-id><pub-id pub-id-type="pmid">20505105</pub-id></citation></ref>
<ref id="B9">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greaves</surname> <given-names>J.</given-names></name> <name><surname>Lemonidis</surname> <given-names>K.</given-names></name> <name><surname>Gorleku</surname> <given-names>O. A.</given-names></name> <name><surname>Cruchaga</surname> <given-names>C.</given-names></name> <name><surname>Grefen</surname> <given-names>C.</given-names></name> <name><surname>Chamberlain</surname> <given-names>L. H.</given-names></name></person-group> (<year>2012</year>). <article-title>Palmitoylation-induced aggregation of cysteine-string protein mutants that cause neuronal ceroid lipofuscinosis</article-title>. <source>J. Biol. Chem.</source> <volume>287</volume>, <fpage>37330</fpage>&#x02013;<lpage>37339</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M112.389098</pub-id><pub-id pub-id-type="pmid">22902780</pub-id></citation></ref>
<ref id="B10">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname> <given-names>M. X.</given-names></name> <name><surname>Wirak</surname> <given-names>G. S.</given-names></name> <name><surname>Zhang</surname> <given-names>Y. Q.</given-names></name> <name><surname>Dai</surname> <given-names>F.</given-names></name> <name><surname>Ginsberg</surname> <given-names>S. D.</given-names></name> <name><surname>Dolzhanskaya</surname> <given-names>N.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Neuronal ceroid lipofuscinosis with DNAJC5/CSP&#x003B1; mutation has PPT1 pathology and exhibit aberrant protein palmitoylation</article-title>. <source>Acta Neuropathol.</source> <volume>131</volume>, <fpage>621</fpage>&#x02013;<lpage>637</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-015-1512-2</pub-id><pub-id pub-id-type="pmid">26659577</pub-id></citation></ref>
<ref id="B11">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hennessy</surname> <given-names>F.</given-names></name> <name><surname>Nicoll</surname> <given-names>W. S.</given-names></name> <name><surname>Zimmermann</surname> <given-names>R.</given-names></name> <name><surname>Cheetham</surname> <given-names>M. E.</given-names></name> <name><surname>Blatch</surname> <given-names>G. L.</given-names></name></person-group> (<year>2005</year>). <article-title>Not all J domains are created equal: implications for the specificity of Hsp40-Hsp70 interactions</article-title>. <source>Prot. Sci.</source> <volume>14</volume>, <fpage>1697</fpage>&#x02013;<lpage>1709</lpage>. <pub-id pub-id-type="doi">10.1110/ps.051406805</pub-id><pub-id pub-id-type="pmid">15987899</pub-id></citation></ref>
<ref id="B12">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kashyap</surname> <given-names>S. S.</given-names></name> <name><surname>Johnson</surname> <given-names>J. R.</given-names></name> <name><surname>McCue</surname> <given-names>H. V.</given-names></name> <name><surname>Chen</surname> <given-names>X.</given-names></name> <name><surname>Edmonds</surname> <given-names>M. J.</given-names></name> <name><surname>Ayala</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title><italic>Caenorhabditis elegans</italic> dnj-14, the orthologue of the DNAJC5 gene mutated in adult onset neuronal ceroid lipofuscinosis, provides a new platform for neuroprotective drug screening and identifies a SIR-2.1-independent action of resveratrol</article-title>. <source>Hum. Mol. Genet.</source> <volume>23</volume>, <fpage>5916</fpage>&#x02013;<lpage>5927</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddu316</pub-id><pub-id pub-id-type="pmid">24947438</pub-id></citation></ref>
<ref id="B13">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noskov&#x000E1;</surname> <given-names>L.</given-names></name> <name><surname>Stranecky</surname> <given-names>V.</given-names></name> <name><surname>Hartmannova</surname> <given-names>H.</given-names></name> <name><surname>Pristoupilova</surname> <given-names>A.</given-names></name> <name><surname>Baresova</surname> <given-names>V.</given-names></name> <name><surname>Ivanek</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis</article-title>. <source>Am. J. Hum. Genet.</source> <volume>89</volume>, <fpage>241</fpage>&#x02013;<lpage>252</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2011.07.003</pub-id><pub-id pub-id-type="pmid">21820099</pub-id></citation></ref>
<ref id="B14">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rozas</surname> <given-names>J. L.</given-names></name> <name><surname>Gomez-Sanchez</surname> <given-names>L.</given-names></name> <name><surname>Mircheski</surname> <given-names>J.</given-names></name> <name><surname>Linares-Clemente</surname> <given-names>P.</given-names></name> <name><surname>Nieto-Gonzalez</surname> <given-names>J. L.</given-names></name> <name><surname>Vazquez</surname> <given-names>M. E.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Motorneurons require cysteine string protein-&#x003B1; to maintain the readily releasable vesicular pool and synaptic vesicle recycling</article-title>. <source>Neuron</source> <volume>74</volume>, <fpage>151</fpage>&#x02013;<lpage>165</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2012.02.019</pub-id><pub-id pub-id-type="pmid">22500637</pub-id></citation></ref>
<ref id="B15">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruiz</surname> <given-names>R.</given-names></name> <name><surname>Biea</surname> <given-names>I. A.</given-names></name> <name><surname>Tabares</surname> <given-names>L.</given-names></name></person-group> (<year>2014</year>). <article-title>&#x003B1;-Synuclein A30P decreases neurodegeneration and increases synaptic vesicle release probability in CSP&#x003B1;-null mice</article-title>. <source>Neuropharmacology</source> <volume>76</volume>(<issue>Pt A</issue>), <fpage>106</fpage>&#x02013;<lpage>117</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.08.032</pub-id><pub-id pub-id-type="pmid">24036317</pub-id></citation></ref>
<ref id="B16">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruiz</surname> <given-names>R.</given-names></name> <name><surname>Casanas</surname> <given-names>J. J.</given-names></name> <name><surname>Sudhof</surname> <given-names>T. C.</given-names></name> <name><surname>Tabares</surname> <given-names>L.</given-names></name></person-group> (<year>2008</year>). <article-title>Cysteine string protein-&#x003B1; is essential for the high calcium sensitivity of exocytosis in a vertebrate synapse</article-title>. <source>Eur. J. Neurosci.</source> <volume>27</volume>, <fpage>3118</fpage>&#x02013;<lpage>3131</lpage>. <pub-id pub-id-type="doi">10.1111/j.1460-9568.2008.06301.x</pub-id><pub-id pub-id-type="pmid">18598257</pub-id></citation></ref>
<ref id="B17">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruiz</surname> <given-names>R.</given-names></name> <name><surname>Lin</surname> <given-names>J.</given-names></name> <name><surname>Forgie</surname> <given-names>A.</given-names></name> <name><surname>Foletti</surname> <given-names>D.</given-names></name> <name><surname>Shelton</surname> <given-names>D.</given-names></name> <name><surname>Rosenthal</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2005</year>). <article-title>Treatment with trkC agonist antibodies delays disease progression in neuromuscular degeneration (NMD) mice</article-title>. <source>Hum. Mol. Genet.</source> <volume>14</volume>, <fpage>1825</fpage>&#x02013;<lpage>1837</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddi189</pub-id><pub-id pub-id-type="pmid">15888478</pub-id></citation></ref>
<ref id="B18">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmitz</surname> <given-names>F.</given-names></name> <name><surname>Tabares</surname> <given-names>L.</given-names></name> <name><surname>Khimich</surname> <given-names>D.</given-names></name> <name><surname>Strenzke</surname> <given-names>N.</given-names></name> <name><surname>de la Villa-Polo</surname> <given-names>P.</given-names></name> <name><surname>Castellano-Munoz</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2006</year>). <article-title>CSP&#x003B1;-deficiency causes massive and rapid photoreceptor degeneration</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>103</volume>, <fpage>2926</fpage>&#x02013;<lpage>2931</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0510060103</pub-id><pub-id pub-id-type="pmid">16477021</pub-id></citation></ref>
<ref id="B19">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname> <given-names>M.</given-names></name> <name><surname>Burre</surname> <given-names>J.</given-names></name> <name><surname>Bronk</surname> <given-names>P.</given-names></name> <name><surname>Zhang</surname> <given-names>Y.</given-names></name> <name><surname>Xu</surname> <given-names>W.</given-names></name> <name><surname>Sudhof</surname> <given-names>T. C.</given-names></name></person-group> (<year>2012a</year>). <article-title>CSP&#x003B1; knockout causes neurodegeneration by impairing SNAP-25 function</article-title>. <source>EMBO J.</source> <volume>31</volume>, <fpage>829</fpage>&#x02013;<lpage>841</lpage>. <pub-id pub-id-type="doi">10.1038/emboj.2011.467</pub-id><pub-id pub-id-type="pmid">22187053</pub-id></citation></ref>
<ref id="B20">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname> <given-names>M.</given-names></name> <name><surname>Burre</surname> <given-names>J.</given-names></name> <name><surname>Sudhof</surname> <given-names>T. C.</given-names></name></person-group> (<year>2011</year>). <article-title>CSP&#x003B1; promotes SNARE-complex assembly by chaperoning SNAP-25 during synaptic activity</article-title>. <source>Nat. Cell Biol.</source> <volume>13</volume>, <fpage>30</fpage>&#x02013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1038/ncb2131</pub-id><pub-id pub-id-type="pmid">21151134</pub-id></citation></ref>
<ref id="B21">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname> <given-names>M.</given-names></name> <name><surname>Burre</surname> <given-names>J.</given-names></name> <name><surname>Sudhof</surname> <given-names>T. C.</given-names></name></person-group> (<year>2012b</year>). <article-title>Proteasome inhibition alleviates SNARE-dependent neurodegeneration</article-title>. <source>Sci. Transl. Med.</source> <volume>4</volume>:<fpage>147r</fpage>a113. <pub-id pub-id-type="doi">10.1126/scitranslmed.3004028</pub-id><pub-id pub-id-type="pmid">22896677</pub-id></citation></ref>
<ref id="B22">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Washbourne</surname> <given-names>P.</given-names></name> <name><surname>Thompson</surname> <given-names>P. M.</given-names></name> <name><surname>Carta</surname> <given-names>M.</given-names></name> <name><surname>Costa</surname> <given-names>E. T.</given-names></name> <name><surname>Mathews</surname> <given-names>J. R.</given-names></name> <name><surname>Lopez-Bendito</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2002</year>). <article-title>Genetic ablation of the t-SNARE SNAP-25 distinguishes mechanisms of neuroexocytosis</article-title>. <source>Nat. Neurosci.</source> <volume>5</volume>, <fpage>19</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1038/nn783</pub-id><pub-id pub-id-type="pmid">11753414</pub-id></citation></ref>
<ref id="B23">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Y. Q.</given-names></name> <name><surname>Chandra</surname> <given-names>S. S.</given-names></name></person-group> (<year>2014</year>). <article-title>Oligomerization of Cysteine String Protein alpha mutants causing adult neuronal ceroid lipofuscinosis</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1842</volume>, <fpage>2136</fpage>&#x02013;<lpage>2146</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2014.07.009</pub-id><pub-id pub-id-type="pmid">25064588</pub-id></citation></ref>
<ref id="B24">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Y. Q.</given-names></name> <name><surname>Henderson</surname> <given-names>M. X.</given-names></name> <name><surname>Colangelo</surname> <given-names>C. M.</given-names></name> <name><surname>Ginsberg</surname> <given-names>S. D.</given-names></name> <name><surname>Bruce</surname> <given-names>C.</given-names></name> <name><surname>Wu</surname> <given-names>T.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Identification of CSP&#x003B1; clients reveals a role in dynamin 1 regulation</article-title>. <source>Neuron</source> <volume>74</volume>, <fpage>136</fpage>&#x02013;<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2012.01.029</pub-id><pub-id pub-id-type="pmid">22500636</pub-id></citation></ref>
<ref id="B25">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zinsmaier</surname> <given-names>K. E.</given-names></name></person-group> (<year>2010</year>). <article-title>Cysteine-string protein&#x00027;s neuroprotective role</article-title>. <source>J. Neurogenet.</source> <volume>24</volume>, <fpage>120</fpage>&#x02013;<lpage>132</lpage>. <pub-id pub-id-type="doi">10.3109/01677063.2010.489625</pub-id><pub-id pub-id-type="pmid">20583963</pub-id></citation></ref>
<ref id="B26">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zinsmaier</surname> <given-names>K. E.</given-names></name> <name><surname>Eberle</surname> <given-names>K. K.</given-names></name> <name><surname>Buchner</surname> <given-names>E.</given-names></name> <name><surname>Walter</surname> <given-names>N.</given-names></name> <name><surname>Benzer</surname> <given-names>S.</given-names></name></person-group> (<year>1994</year>). <article-title>Paralysis and early death in cysteine string protein mutants of Drosophila</article-title>. <source>Science</source> <volume>263</volume>, <fpage>977</fpage>&#x02013;<lpage>980</lpage>. <pub-id pub-id-type="doi">10.1126/science.8310297</pub-id><pub-id pub-id-type="pmid">8310297</pub-id></citation></ref>
<ref id="B27">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zinsmaier</surname> <given-names>K. E.</given-names></name> <name><surname>Hofbauer</surname> <given-names>A.</given-names></name> <name><surname>Heimbeck</surname> <given-names>G.</given-names></name> <name><surname>Pflugfelder</surname> <given-names>G. O.</given-names></name> <name><surname>Buchner</surname> <given-names>S.</given-names></name> <name><surname>Buchner</surname> <given-names>E.</given-names></name></person-group> (<year>1990</year>). <article-title>A cysteine-string protein is expressed in retina and brain of Drosophila</article-title>. <source>J. Neurogenet.</source> <volume>7</volume>, <fpage>15</fpage>&#x02013;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.3109/01677069009084150</pub-id><pub-id pub-id-type="pmid">2129171</pub-id></citation></ref>
</ref-list>
</back>
</article>